Some cannabis producers are funding research on pain management to fill the void, including British Columbia-based Tilray. The company funded a survey recently published in the International Journal of Drug Policy on substituting cannabis for prescription opioids and other substances. “There is a growing amount of evidence suggesting that cannabis is a safer substitute for many prescription drugs, particularly opioids,” said Philippe Lucas, vice president of patient research and access at Tilray. “Increasing the understanding and acceptance of medical cannabis as a relatively safe and effective treatment for chronic pain and other conditions could reduce the medical community’s dependence on opioids.”
Read more in the Canadian Medical Association Journal News.